拜耳(BAYRY.US)宣布Sevabertinib获FDA优先审评 用于治疗HER2突变NSCLC

智通财经
29 May

智通财经APP获悉,5月28日,拜耳(BAYRY.US)宣布Sevabertinib(BAY 2927088)获FDA授予优先审评资格,用于治疗已经接受过一种系统治疗的HER2突变非小细胞肺癌患者。

Sevabertinib为拜耳的核心管线之一,此前已经获得中国、美国的突破疗法认证,目前正在推进三期验证性临床SOHO-02,以及HER2激活突变泛瘤种的二期临床panSOHO。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10